Trevi Therapeutics (TRVI) Stock Forecast, Price Target & Predictions
TRVI Stock Forecast
Trevi Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 256.08% upside from TRVI’s last price of $3.37) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
TRVI Price Target
The average price target for Trevi Therapeutics (TRVI) is $12.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 256.08% upside from TRVI's last price of $3.37.
TRVI Analyst Ratings
According to 6 Wall Street analysts, Trevi Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TRVI stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Trevi Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 09, 2022 | Leland Gershall | Oppenheimer | $12.00 | $3.95 | 203.80% | 256.08% |
The latest Trevi Therapeutics stock forecast, released on Jul 09, 2022 by Leland Gershall from Oppenheimer, set a price target of $12.00, which represents a 203.80% increase from the stock price at the time of the forecast ($3.95), and a 256.08% increase from TRVI last price ($3.37).
Trevi Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.37 | $3.37 | $3.37 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Trevi Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Trevi Therapeutics's last price of $3.37. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 30, 2024 | Raymond James | - | Outperform | Initialise |
| Aug 30, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Aug 19, 2024 | EF Hutton | - | Buy | Initialise |
| Jun 12, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Nov 11, 2022 | Needham | Buy | Buy | Hold |
| Jun 30, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 29, 2022 | Needham | Buy | Buy | Hold |
| May 25, 2022 | Oppenheimer | - | Outperform | Initialise |
Trevi Therapeutics's last stock rating was published by Raymond James on Aug 30, 2024. The company Initialise its TRVI rating from "null" to "Outperform".
Trevi Therapeutics Financial Forecast
Trevi Therapeutics Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $67.56M | $63.74M | $62.46M | $61.19M | - | - | - | - | - | - | - |
| High Forecast | $67.56M | $63.74M | $62.46M | $61.19M | - | - | - | - | - | - | - |
| Low Forecast | $67.56M | $63.74M | $62.46M | $61.19M | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Trevi Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TRVI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Trevi Therapeutics EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict TRVI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Trevi Therapeutics's previous annual EBITDA (undefined) of $NaN.
Trevi Therapeutics Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-12.12M | $-12.12M | $-12.88M | $-12.12M | $-11.52M | $-12.12M | $-10.97M |
| High Forecast | - | - | - | - | $-12.12M | $-12.12M | $-12.88M | $-12.12M | $-11.52M | $-9.09M | $-10.97M |
| Low Forecast | - | - | - | - | $-12.12M | $-12.12M | $-12.88M | $-12.12M | $-11.52M | $-13.14M | $-10.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Trevi Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TRVI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Trevi Therapeutics SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Trevi Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TRVI last annual SG&A of $NaN (undefined).
Trevi Therapeutics EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-0.12 | $-0.12 | $-0.13 | $-0.12 | $-0.11 | $-0.12 | $-0.11 |
| High Forecast | - | - | - | - | $-0.12 | $-0.12 | $-0.13 | $-0.12 | $-0.11 | $-0.09 | $-0.11 |
| Low Forecast | - | - | - | - | $-0.12 | $-0.12 | $-0.13 | $-0.12 | $-0.11 | $-0.13 | $-0.11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Trevi Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TRVI previous annual EPS of $NaN (undefined).
Trevi Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SQZ | SQZ Bio | $0.44 | $400.00 | 90809.09% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CHRS | Coherus BioSciences | $1.30 | $9.00 | 592.31% | Hold |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| TRVI | Trevi Therapeutics | $3.37 | $12.00 | 256.08% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| BCAB | BioAtla | $1.81 | $5.00 | 176.24% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| PRLD | Prelude Therapeutics | $2.77 | $6.25 | 125.63% | Sell |
| FHTX | Foghorn Therapeutics | $9.72 | $18.00 | 85.19% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| ORIC | ORIC Pharmaceuticals | $9.89 | $17.00 | 71.89% | Buy |
| BOLT | Bolt Biotherapeutics | $0.61 | $1.00 | 63.93% | Hold |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
TRVI Forecast FAQ
Is Trevi Therapeutics a good buy?
Yes, according to 6 Wall Street analysts, Trevi Therapeutics (TRVI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of TRVI's total ratings.
What is TRVI's price target?
Trevi Therapeutics (TRVI) average price target is $12 with a range of $12 to $12, implying a 256.08% from its last price of $3.37. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Trevi Therapeutics stock go up soon?
According to Wall Street analysts' prediction for TRVI stock, the company can go up by 256.08% (from the last price of $3.37 to the average price target of $12), up by 256.08% based on the highest stock price target, and up by 256.08% based on the lowest stock price target.
Can Trevi Therapeutics stock reach $5?
TRVI's average twelve months analyst stock price target of $12 supports the claim that Trevi Therapeutics can reach $5 in the near future.
What are Trevi Therapeutics's analysts' financial forecasts?
Trevi Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-49.258M (high $-49.258M, low $-49.258M), average SG&A $0 (high $0, low $0), and average EPS is $-0.487 (high $-0.487, low $-0.487). TRVI's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $254.95M (high $254.95M, low $254.95M), average EBITDA is $0 (high $0, low $0), average net income is $0 (high $0, low $0), average SG&A $0 (high $0, low $0), and average EPS is $0 (high $0, low $0).